L. Assoumou

发表

Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study

R. Tubiana, C. Katlama, D. Bendetowicz, 2021, Infectious Diseases Now.

Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing

C. Delaugerre, J. Izopet, S. Raymond, 2018, AIDS.

Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients

G. Carcelain, A. Samri, C. Katlama, 2010, AIDS.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy

D. Costagliola, M. Alhenc-Gelas, C. Didier, 2016, Journal of acquired immune deficiency syndromes.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study

V. Calvez, C. Katlama, Y. Yazdanpanah, 2019, Pharmacotherapy.

Determinants of Low-Density Lipoprotein Particle Diameter during Antiretroviral Therapy Including Protease Inhibitors in HIV-1-Infected Patients

D. Costagliola, P. Giral, D. Bonnefont-Rousselot, 2012, Antiviral therapy.

Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study

C. Katlama, D. Costagliola, J. Capeau, 2022, Journal of acquired immune deficiency syndromes.

Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.

A. Desnoyer, D. Costagliola, C. Lebbé, 2016, AIDS research and human retroviruses.

High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors

D. Costagliola, J. Capeau, J. Bastard, 2011, AIDS.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV‐infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial

C. Delaugerre, D. Costagliola, J. Lelièvre, 2019, HIV medicine.

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.

H. Stellbrink, M. Johnson, E. Martinez, 2021, The Journal of antimicrobial chemotherapy.

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.

C. Katlama, D. Costagliola, R. Murphy, 2009, AIDS.

Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia

V. Calvez, G. Carcelain, C. Katlama, 2016, AIDS.

Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.

D. Podzamczer, C. Katlama, J. Gatell, 2022, The Journal of antimicrobial chemotherapy.

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

D. Costagliola, P. Giral, F. Boccara, 2010, AIDS.

Piloting a surveillance system for HIV drug resistance in the European Union

M. Poljak, A. Pharris, A. Amato-Gauci, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery

C. Katlama, P. Coriat, D. Costagliola, 2019, HIV medicine.

HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection.

C. Delaugerre, M. Lê, G. Peytavin, 2021, The Journal of infectious diseases.

Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

C. Katlama, B. Autran, D. Costagliola, 2015, AIDS (London).

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

V. Calvez, C. Delaugerre, S. Yerly, 2017, The Journal of antimicrobial chemotherapy.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

C. Katlama, D. Costagliola, G. Peytavin, 2014, The Journal of antimicrobial chemotherapy.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

V. Calvez, C. Delaugerre, S. Yerly, 2015, The Journal of antimicrobial chemotherapy.

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer

A. Samri, C. Katlama, B. Autran, 2022, Cells.

Expression pattern of the CXCL12/CXCR4–CXCR7 trio in Kaposi sarcoma skin lesions

A. Desnoyer, N. Dupin, C. Deback, 2016, The British journal of dermatology.

Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection

C. Delaugerre, D. Costagliola, Y. Lévy, 2020, Annals of Internal Medicine.

Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.

D. Costagliola, P. Giral, D. Bonnefont-Rousselot, 2017, Comptes rendus biologies.

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in

V. Calvez, C. Katlama, D. Costagliola, 2009, AIDS.

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

F. Brun-Vézinet, D. Kuritzkes, A. Zolopa, 2010, AIDS.

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

B. Clotet, J. Martinez-Picado, J. Romeu, 2011, The Journal of infectious diseases.

Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study

C. Charpentier, Y. Yazdanpanah, D. Costagliola, 2022, BMC Infectious Diseases.

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

V. Calvez, C. Katlama, B. Autran, 2015, The lancet. HIV.

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

R. Tubiana, C. Katlama, D. Costagliola, 2022, European Journal of Clinical Microbiology & Infectious Diseases.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir

C. Rouzioux, D. Costagliola, A. Mélard, 2010, Journal of medical virology.

Emtricitabine Seminal Plasma and Blood Plasma Population Pharmacokinetics in HIV-Infected Men in the EVARIST ANRS-EP 49 Study

C. Rouzioux, S. Urien, M. Suzan-Monti, 2015, Antimicrobial Agents and Chemotherapy.

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

V. Calvez, C. Katlama, D. Costagliola, 2008, The Journal of antimicrobial chemotherapy.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

C. Rouzioux, P. Frange, Laurent Tran, 2015, The Journal of antimicrobial chemotherapy.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

V. Calvez, C. Charpentier, C. Delaugerre, 2017, The Journal of antimicrobial chemotherapy.

Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia

C. Katlama, D. Costagliola, C. Roux, 2013, AIDS.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

A. Samri, D. Costagliola, G. Peytavin, 2016, The Journal of antimicrobial chemotherapy.

Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.

O. Traoré, V. Calvez, R. Tubiana, 2007, Journal of acquired immune deficiency syndromes.

Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients

C. Rouzioux, S. Urien, M. Suzan-Monti, 2016, Antimicrobial Agents and Chemotherapy.

Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in France

P. Frange, S. Blanche, I. Funck-Brentano, 2016, The open AIDS journal.

Propensity score analysis of artesunate versus quinine for severe imported Plasmodium falciparum malaria in France.

R. Piarroux, D. Costagliola, E. Kendjo, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis

C. Delaugerre, Y. Lévy, J. Izopet, 2021, PLoS pathogens.

No HIV-1 molecular evolution on long term antiretroviral therapy initiated during primary HIV-1 infection.

V. Calvez, R. Tubiana, C. Katlama, 2020, AIDS.

T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection

C. Rouzioux, D. Costagliola, C. Didier, 2014, AIDS.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2013, The Journal of antimicrobial chemotherapy.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

V. Calvez, G. Carcelain, R. Tubiana, 2016, AIDS.

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

V. Calvez, B. Clotet, C. Katlama, 2016, AIDS.

A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control

C. Rouzioux, D. Costagliola, P. Girard, 2015, AIDS.

A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.

C. Katlama, Y. Yazdanpanah, M. Duracinsky, 2022, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma

D. Costagliola, A. Balde, L. Assoumou, 2021, Cancers.

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Inge Christoffer Olsen, F. Lund-Johansen, Mariana H. S. Bernardo, 2023, Critical Care.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

C. Katlama, D. Costagliola, E. Martinez, 2019, The Journal of antimicrobial chemotherapy.

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

B. Walker, V. Calvez, B. Clotet, 2008, AIDS.

Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials: Experience from EU‐Response and conect4children consortia

Inge Christoffer Olsen, R. Fernandes, Y. Yazdanpanah, 2023, British journal of clinical pharmacology.

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

V. Calvez, D. Podzamczer, C. Delaugerre, 2020, The Journal of antimicrobial chemotherapy.

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data

Philippe Flandre, Vincent Calvez, Jean Michel Molina, 2012, AIDS research and treatment.

Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.

C. Delaugerre, C. Katlama, D. Costagliola, 2022, The lancet. HIV.

Prevalence of HIV-1 Drug Resistance in Treated Patients: A French Nationwide Study

F. Brun-Vézinet, C. Delaugerre, S. Yerly, 2007, Journal of acquired immune deficiency syndromes.

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

R. Tubiana, C. Katlama, L. Cuzin, 2022, Journal of acquired immune deficiency syndromes.

HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.

C. Rouzioux, D. Costagliola, M. Suzan-Monti, 2016, The Journal of antimicrobial chemotherapy.

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

Inge Christoffer Olsen, F. Lund-Johansen, L. Dodd, 2023, The Lancet Respiratory Medicine.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study

C. Katlama, P. Bedossa, D. Costagliola, 2019, Journal of acquired immune deficiency syndromes.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

C. Delaugerre, S. Yerly, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

H. Stellbrink, J. Gatell, M. Johnson, 2017, AIDS.

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy–Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals

R. Tubiana, C. Katlama, O. Godin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor

D. Costagliola, P. Giral, D. Bonnefont-Rousselot, 2012, AIDS.

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

V. Calvez, C. Katlama, D. Costagliola, 2015, The Journal of antimicrobial chemotherapy.

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

V. Calvez, C. Katlama, D. Costagliola, 2007, AIDS.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France

V. Calvez, C. Charpentier, J. Izopet, 2019, The Journal of antimicrobial chemotherapy.

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

M. Altfeld, B. Clotet, C. Katlama, 2011, AIDS.

Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy

C. Rouzioux, D. Costagliola, Y. Lévy, 2010, PloS one.

Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study.

C. Katlama, P. Bedossa, D. Costagliola, 2022, Clinical Gastroenterology and Hepatology.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.

P. Morlat, D. Costagliola, J. Alvarez, 2023, The Journal of antimicrobial chemotherapy.

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.

V. Calvez, C. Katlama, M. Lê, 2015, The Journal of antimicrobial chemotherapy.

Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc.

K. Clément, C. Katlama, J. Capeau, 2021, AIDS.

Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.

C. Katlama, D. Costagliola, J. Capeau, 2020, AIDS.

Impact of ART classes on the increasing risk of cerebral small-vessel disease in middle-aged, well-controlled, cART-treated, HIV-infected individuals.

R. Tubiana, C. Katlama, O. Godin, 2019, Journal of acquired immune deficiency syndromes.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

R. Breban, A. Samri, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.

D. Costagliola, L. Assoumou, P. Flandre, 2010, The Journal of antimicrobial chemotherapy.

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area

V. Calvez, R. Tubiana, C. Katlama, 2022, Journal of Infection.

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

C. Katlama, E. Caumes, M. Valantin, 2021, Infectious Diseases Now.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007 – 12: impact on susceptibility to ﬁrst-line strategies

C. Rouzioux, P. Frange, Laurent Tran, 2015 .

Perception of PrEP‐related stigma in PrEP users: Results from the ANRS‐PREVENIR cohort

D. Costagliola, B. Spire, C. Protière, 2023, HIV medicine.

Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial)

C. Katlama, D. Costagliola, J. Alvarez, 2020, British journal of clinical pharmacology.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

R. Tubiana, C. Katlama, M. Lê, 2018, The Journal of antimicrobial chemotherapy.

Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study

V. Calvez, C. Katlama, G. Peytavin, 2012, HIV clinical trials.

Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy

C. Rouzioux, D. Costagliola, Y. Lévy, 2010, PloS one.

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

R. Tubiana, C. Katlama, F. Raffi, 2020, The Journal of antimicrobial chemotherapy.

C. Katlama, D. Costagliola, E. Martinez, 2020, The Journal of antimicrobial chemotherapy.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

V. Calvez, C. Delaugerre, S. Yerly, 2008, The Journal of antimicrobial chemotherapy.

V. Calvez, C. Katlama, D. Costagliola, 2008, Journal of Antimicrobial Chemotherapy.

Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy

V. Calvez, G. Carcelain, R. Tubiana, 2010, AIDS.

Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set

V. Calvez, V. Miller, L. Assoumou, 2013, PloS one.

Pharmacokinetics of high dosage of linezolid in two morbidly obese patients.

V. Calvez, C. Katlama, V. Ranieri, 2015, The Journal of antimicrobial chemotherapy.

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

L. Assoumou, C. Fletcher, Frank A Post, 2024, The Lancet HIV.

SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 – A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts

C. Delaugerre, F. Carrat, D. Costagliola, 2022, Open Forum Infectious Diseases.

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

C. Delaugerre, F. Carrat, D. Costagliola, 2022, Open forum infectious diseases.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir

C. Rouzioux, D. Costagliola, A. Mélard, 2010, Journal of medical virology.